Avidity Biosciences, Inc. - Common Stock (RNA)

Let's have a look at the gap up and gap down stocks in today's session.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Avidity's del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne muscular dystrophy after one year.

Avidity Biosciences (RNA) stock shows a strong technical breakout setup with high momentum, trading above key moving averages in a bullish trend.

The company is focused on treatments for forms of muscular dystrophy.

Avidity shares early del-brax FSHD data showing improved mobility, strength, and safety; Phase 3 FORWARD trial now underway.

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.